Trials / Completed
CompletedNCT03009344
A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
A Phase 1 Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, single-arm, open-label, Phase 1 study to assess the tolerability, safety, pharmacokinetics, and preliminary anti-tumor activity of tazemetostat in participants with relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tazemetostat | Tazemetostat tablets. |
Timeline
- Start date
- 2017-01-10
- Primary completion
- 2017-07-12
- Completion
- 2020-06-17
- First posted
- 2017-01-04
- Last updated
- 2022-11-10
- Results posted
- 2022-11-10
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03009344. Inclusion in this directory is not an endorsement.